Our venture capital fund focuses investments on early-stage life sciences companies looking to improve people’s outcomes with cancer.

Recent News

C4-logo-400
09/23/2019

C4 Therapeutics Announces the Addition of Ryan B. Corcoran, M.D., Ph.D. to the Scientific Advisory Board

READ MORE
wugen-logo-400
04/30/2019

Wugen Adds to Leadership Team as Company Continues to Lay Groundwork for Future Expansion

READ MORE
wugen-logo-400
03/26/2019

WUGEN Expands Leadership Team with Appointment of a Vice President of Research and Development and a Vice President of Product Development

READ MORE
C4-logo-400
03/14/2019

C4 Therapeutics Appoints Adam Crystal, M.D., Ph.D. as Chief Medical Officer

READ MORE
wugen-logo-400
02/20/2019

WUGEN Presents New Data for Key CAR-T Platform at the 2019 Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR

READ MORE
C4-logo-400
01/04/2019

Biogen and C4 Therapeutics Enter into Strategic Collaboration to Discover and Develop Potential New Treatments for Neurological Conditions

READ MORE
C4-logo-400
01/04/2019

C4 Therapeutics Announces Transformation of Strategic Collaboration to Discover and Develop Degrader-Based Medicines with Roche

READ MORE
wugen-logo-400
12/03/2018

WUGEN Presents Updated Preclinical Data on Novel Allogeneic CAR-T Platform at ASH Annual Meeting

READ MORE
wugen-logo-400
11/01/2018

WUGEN Announces Presentations at American Society of Hematology Annual Meeting

READ MORE

PORTFOLIO HIGHLIGHTS

WUGEN Logo
White C4 Therapeutics logo
Geneoscopy logo
NextRNA Logo
CareVet Logo
microbial-logo-header300